OXYTOCIN

Sexual Function & LibidoPrescription Available

Extensive human trial data across 30 randomized controlled studies, though results vary significantly by condition and population studied. One of the few peptides with established clinical use and FDA approval, but therapeutic applications beyond obstetrics remain inconsistent.

Studied extensively by researchers investigating autism spectrum disorders, social anxiety, depression, and obesity, with particular interest from psychiatric and behavioral neuroscience labs.

FDA Status

FDA Approved

Since Feb 2026

Evidence

Strong

Studies

30 total, 30 human

What is OXYTOCIN?

Often called the 'love hormone,' this nine-amino acid peptide plays a central role in childbirth, breastfeeding, and pair bonding across mammalian species. Researchers have expanded beyond its reproductive functions to investigate potential applications in autism spectrum disorders, anxiety, and social cognition. The pharmaceutical form (Pitocin) has been safely used in obstetrics for decades to induce labor contractions.

The peptide activates specific oxytocin receptors distributed throughout the brain and body, triggering cascades that influence everything from uterine contractions to neural circuits governing trust and empathy. In the brain, it enhances GABA neurotransmission while dampening the hypothalamic-pituitary-adrenal stress axis, creating its characteristic calming and prosocial effects. The same receptor system that helps mothers bond with newborns also appears to modulate social behavior more broadly.

What the Research Shows

Robust evidence base with 30 randomized controlled trials exclusively in human subjects, representing some of the strongest clinical data available for any research peptide.

Thirty randomized controlled trials in humans examined oxytocin across psychiatric and metabolic conditions, with mixed results: while the combination of probiotic PS128 with oxytocin improved social responsiveness in autism spectrum disorder, oxytocin nasal spray alone showed no significant benefit for social interaction in young children with autism, did not reduce weight or improve body composition in adults with obesity, produced differential effects on depression and suicidal ideation depending on personality profiles (with potential therapeutic alliance worsening in some patients), and demonstrated no significant benefit for negative symptoms or cognitive impairments in schizophrenia when combined with galantamine.